Overview

Evaluating the Safety, Tolerability, Pharmacokinetics and Receptor Occupancy of BMS-984923

Status:
Recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This project seeks to develop a novel disease-modifying compound for Alzheimer's disease (AD).
Phase:
Phase 1
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Aging (NIA)